Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children

Vaccine

Volumn 30, Issue 40, 2012, Pages 5880-5885

  van der Linden, Mark ^a   Weiß, Susanne ^b   Falkenhorst, Gerhard ^c   Siedler, Annette ^c   Imöhl, Matthias ^a   von Kries, Rüdiger ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Epidemiology; Germany; Invasive pneumococcal disease; Non meningitis IPD; Pneumococcal conjugate vaccination; Pneumococcal meningitis; Serotype replacement

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ARTICLE; BACTERIUM ISOLATION; CHILD; CHILDHOOD DISEASE; FEMALE; GERMANY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GERMANY; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84864803410     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.068     Document Type: Article

References (28)

1. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
2. De Carvalho Gomes H., Muscat M., Monnet D.L., Giesecke J., Lopalco P.L. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009, 14(March (12)).
3. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(December (9807)):1962-1973.
4. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Andersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28(March (14)):2642-2647.
5. Vestrheim D.F., Hoiby E.A., Bergsaker M.R., Ronning K., Aaberge I.S., Caugant D.A. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010, 28(March (10)):2214-2221.
6. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(October (10)):760-768.
7. Bingen E., Levy C., Varon E., de La Rocque F., Boucherat M., d'Athis P., et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis 2008, 27(March (3)):191-199.
8. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg Infect Dis 2010, 16(May (5)):816-823.
9. Dias R., Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 2007, 51(October (1)):35-42.
10. Ruckinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27(June (31)):4136-4141.
11. Robert-Koch-Institut. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2001; plus Anhang: Begründung der STIKO-Empfehlung zur Pneumokokken-Impfung. Epidemiologisches Bull 2001, 28.
12. Robert-Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Begründungen zur allgemeinen Empfehlung der Impfungen gegen Pneumokokken und Meningokokken im Säuglings- und Kindesalter. Epidemiologisches Bull 2006, 31.
13. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360(January (3)):244-256.
14. Jefferson T., Ferroni E., Curtale F., Giorgi Rossi P., Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis 2006, 6(July (7)):405-410.
15. Ruggeberg J.U., Ketteler K., MacKenzie C.R., Von Kries R., Reinert R.R., Schroten H. Blood culture sampling rates at a German pediatric university hospital and incidence of invasive pneumococcal disease. Infection 2004, 32(April (2)):78-81.
16. von Kries R., Siedler A., Schmitt H.J., Reinert R.R. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 2000, 31(August (2)):482-487.
17. Ruckinger S., von Kries R., Reinert R.R., van der Linden M., Siedler A. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 2008, 26(July (2932)):3984-3986.
18. Gobel U., Heinrich B., Krauth K.A., Steingruber H.J., von Kries R. [Process and outcome quality of the German Paediatric Surveillance Unit (ESPED)]. Klin Padiatr 2010, 222(March (2)):92-97.
19. LaPorte R.E., McCarty D.J., Tull E.S., Tajima N. Counting birds, bees, and NCDs. Lancet 1992, 339(February (8791)):494-495.
20. StatistischesBundesamt. Federal Statistical Office of Germany. Tabelle B15. A1 Bevölkerung nach Alters- und Geburtsjahren 2000-2010.
21. Armitage P., Berry G. Statistical Methods in Medical Research 1994, Blackwell, London. 3rd ed.
22. Black S.B., Shinefield H.R., Hansen J., Elvin L., Laufer D., Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001, 20(December (12)):1105-1107.
23. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54(September (36)):893-897.
24. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(April (9568)):1179-1186.
25. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010, 85(October (43)):434-436.
26. Theidel U., Braem A., Rückinger S. Bestimmung einer Durchimpfungsrate zur Pneumokokkenimpfung bei Säuglingen anhand von GKV-Routinedaten. Epidemiologisches Bull 2011, 32.
27. Rückinger S., van der Linden M., Reinert R.R., von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: an analysis using the indirect cohort method. Vaccine 2010, 28(July (31)):5012-5016.
28. Koshy E., Murray J., Bottle A., Sharland M., Saxena S. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010, 65(September (9)):770-774.